195 related articles for article (PubMed ID: 27432585)
1. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
2. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
3. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
[TBL] [Abstract][Full Text] [Related]
5. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.
Zhang X; Yang C; Zhou J; Huo M
Small; 2016 Jul; 12(26):3578-90. PubMed ID: 27244649
[TBL] [Abstract][Full Text] [Related]
8. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
9. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.
Zhang Y; Wang X; Wang J; Zhang X; Zhang Q
Pharm Res; 2011 May; 28(5):1167-78. PubMed ID: 21340573
[TBL] [Abstract][Full Text] [Related]
10. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.
Niu J; Huang A; Xiao Y; Su Z; Li H; Ping Q; Bao X; Li S; Chen Y; Sun M
J Drug Target; 2013 May; 21(5):415-26. PubMed ID: 23597028
[TBL] [Abstract][Full Text] [Related]
11. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
[TBL] [Abstract][Full Text] [Related]
13. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Iwase Y; Maitani Y
Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.
Dubey N; Varshney R; Shukla J; Ganeshpurkar A; Hazari PP; Bandopadhaya GP; Mishra AK; Trivedi P
Drug Deliv; 2012 Apr; 19(3):132-42. PubMed ID: 22428685
[TBL] [Abstract][Full Text] [Related]
15. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
[TBL] [Abstract][Full Text] [Related]
16. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
17. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate.
Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K
Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells.
Wang Q; Zhu R; Wang M; Xing S; Li L; He Y; Cao W; Gao D
Nanomedicine (Lond); 2017 Apr; 12(8):927-940. PubMed ID: 28338414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
